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“If you want something to be done, just do it yourself.” 
Charlie Teo 
 
 
“All truth passes through three stages: first, it is ridiculed;  
second, it is violently opposed;  
third, it is accepted as being self-evident.” 
Arthur Schopenhauer 
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1. LIST OF ABBREVIATIONS 
 
AA: Anaplastic astrocytoma 
BBB: Blood-brain barrier 
CHT: Chemotherapy 
EOR: Extent of reception 
eV: ElettronVolt 
FDA: Food and Drug Administration 
FLIM: Fluorescence lifetime imaging microscopy 
GA: General anesthesia 
GBM: Glioblastoma multiforme 
GFAP: Glial fibrillary acidic protein 
GTR: Gross total resection 
HGG: High grade gliomas 
ICG: Indocyanin green 
iMRI: Intraoperative magnetic resonance imaging 
i.v.: Intravenous 
KPS: Karnofsky performance scale 
L: Left (tables only) 
LGG: Low-grade gliomas 
MG: Malignant gliomas 
MGMT: O-6-methylguanine-DNA methyltransferase  
MMSE: Mini mental state evaluation  
MRI: Magnetic resonance imaging 
NADH: Reduced nicotinamide adenine dinucleotide  
NIHSS: US National Institute of Health Stroke Scale 
OS: Overall survival 
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PFS: Progression-free survival  
PpIX: Protoporphyrin IX 
Pt(s).: Patient(s) (tables only) 
R: Right (tables only) 
RANO: Response assessment in neuro-oncology 
RT: Radiotherapy 
S0: Ground state  
S1: Higher energy state 
TMZ: Temozolomide 
TR-LIFS: Time-resolved fluorescence spectroscopy  
UV: Ultraviolet 
VP: Venticulo-peritoneal 
vs: Versus 
WHO: World Health Organization 
5-ALA: 5-aminolevulenic acid 
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2. INTRODUCTION 
 
Malignant Gliomas (MG), or High Grade Gliomas (HGG), are aggressive 
primary brain tumors with poor prognosis despite maximal therapy available 
consisting in a combination of surgery, chemotherapy (CHT) and 
radiotherapy (RT) [47]. Gliomas account for nearly 80% of primary malignant 
brain tumors, contributing to approximately 13.000 deaths and 18.000 new 
cases annually in the United States [70]. This devastating disease accounts 
for more years of life lost than any other type of tumor [70]. According to the 
current World Health Organization (WHO) grading system classification, MG 
include grade III and IV gliomas [47, 84]. Glioblastoma multiforme (GBM), 
grade IV WHO glioma, is the most common type of glioma and carries a very 
poor prognosis. The current standard of care results in an average life 
expectancy of 14 months after diagnosis [70].  
Though the role of surgery in MG remains controversial, there are some 
retrospective studies and one prospective study that suggested a significant 
impact of the extent of resection (EOR) on the outcome of patients affected 
by MG [37, 43, 48, 77]. However, the surgical removal of the whole 
enhancing mass on the preoperative Magnetic Resonance Imaging (MRI), 
the so called gross total resection (GTR), was reported to be feasible only in 
a low percentage of cases [43, 48], due to intraoperative difficulties in tumor 
tissue recognition at the margin of the resection [89]. 
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A number of new technical tools, such as neuronavigation [98], intraoperative 
magnetic resonance imaging (iMRI) [36, 46, 55] and cranial ultrasound [23, 
91], were therefore developed to obtain better surgical results and they are 
part of the common armamentarium used for this king of surgery. 
Nevertheless, only a randomized trial on iMRI demonstrated a class I 
evidence of its application on EOR [71]; iMRI guided surgery, though, is 
significantly more time consuming, it can interfere with the surgical workflow 
(compatibility of instruments or equipment) [36] and, finally, may not be 
available in every center due to high cost of installation and maintenance. 
Photodynamic detection, which takes advantages of a photosensitive drug 
(fluorophore) specific for the tumor tissue and with a well-defined range of 
fluorescence, has been used in neurosurgery for removal of HGG [45, 53].  
This study aims to evaluate the safety and the efficacy of fluorescein guided 
surgery for removal of MG.  
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3. FLUORESCENCE OVERVIEW 
 
3.1 Basic mechanisms of fluorescence 
Electromagnetic radiation can excite electrons in atoms or molecules from 
their ground state (S0) to a higher energy state (S1). Excitation energy 
between 1.5 elettronVolt (eV) and 3.5 eV is required for aromatic organic 
molecules; this corresponds to wavelengths between 800 nm and 300 nm. 
Fluorescence occurs when electrons relax from their S1 to S0 state by 
emitting photons of light. Excitation light is of lower wavelength (higher 
frequency and higher energy) and the corresponding fluorescent radiation is 
of longer wavelengths (lower frequency and lower energy); this phenomenon 
is known as the Stokes shift [44, 45, 94]. This transfer typically happens in 
pico- to nano-seconds.  
 
3.2 Fluorescence lifetime 
Fluorescence lifetime is the average amount of time a fluorophore remains in 
the excited state following excitation. Different molecular constituents of cells 
display intrinsic auto-fluorescence. As a result of the variability of cellular 
(cytosol, mitochondria, et cetera) or tissue (normal, necrotic, neoplastic, et 
cetera) environments in which these molecules are found, variations in 
fluorescence lifetimes can be used as a possible mechanism of contrast to 
distinguish tissue [6, 7, 32, 49, 94, 100]. Several groups have reported on the 
utility of fluorescence lifetime for delineating normal from pathologic tissue 
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[10, 12, 74]. A major advantage of using time-resolved fluorescence 
assessments using either spectroscopic or imaging devices is that lifetime 
assessments are independent of blood, irregular brain surfaces, or tissue 
illumination, unlike measurements of fluorescence intensity alone [3, 4, 10]. 
Time-resolved fluorescence spectroscopy (TR-LIFS) measures fluorescence 
lifetime, but rather than imaging mode, it does so using a point spectroscopy 
device [6-8, 49, 61, 62, 94, 100]. Butte et al. [6, 7] previously demonstrated 
the implementation of TR-LIFS to detect fluorescence lifetime differences 
between normal brain tissue and glioma ex vivo and more recently reported 
the potential of applying TRLIFS for intraoperative diagnosis of gliomas. 
Normal cortex and white matter showed two fluorescence peaks at 390 nm 
and 460 nm, whereas the 390 nm emission peak was absent in low-grade 
gliomas (LGG) (N = 5) and reduced HGG (N = 9) [6]. These differences 
found in vivo suggest that TR-LIFS may function as potential adjuncts for 
facilitating delineation of the brain-tumor interface; however, additional 
studies are needed to validate its accuracy as an intraoperative tool for 
delineation of brain tumors. 
Fluorescence lifetime imaging microscopy (FLIM) is an imaging technique 
used by Sun et al. [85] to determine the practicality of using an endoscopic 
fluorescence lifetime imaging for intraoperative identification of GBM. These 
authors evaluated the technique by validation between FLIM and MRI, 
intraoperative gross judgment, and gross pathological assessment. In this 
study, the FLIM instrument was adapted onto an endoscopic probe which 
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was positioned perpendicular to tissue surface. The fluorescence intensity 
and lifetime centered at 460 nm (major emission band for reduced 
nicotinamide adenine dinucleotide (NADH)) were significantly weaker and 
longer, respectively, in GBM compared to normal parenchyma following 
ultraviolet (UV) excitation. This pilot study presented initial results on the 
potential application of FLIM for intraoperative tumor identification. 
 
3.3 Fluorophores 
  
3.3.1 5-aminolevulenic acid (5-ALA) 
Formation of ALA is the initial rate-limiting step in the porphyrin synthesis 
pathway that ultimately leads to heme-synthesis. Exogenous administration 
of 5-ALA functions as a pro-drug, which is then metabolized and promotes 
accumulation of fluorescent protoporphyrin IX (PpIX) in tissues through the 
hemi-biosynthesis pathway [95]. Although malignant gliomas show an 
increased accumulation of PpIX, the exact mechanism responsible for 
excess PpIX production in neoplastic cells after exogenous 5-ALA 
administration is not yet fully understood. The main mechanism of 
accumulation of PpIX in malignant tissue was initially believed to be the 
result of 5-ALA crossing a disrupted blood-brain barrier (BBB). 
However, several studies have demonstrated that this is not the only 
mechanism, and that and specificity for the malignant cells might exist. 
Stummer et al. [81] studied 144 biopsies obtained from 66 patients. The 
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intensity of PpIX fluorescence was spectrographically assessed. 
Histopathologic analysis was conducted in terms of cellular density, MIB-l 
labeling index (as an indicator of proliferative activity) and the area of CD-31 
staining was measured to determine neovascularity. A multi regression 
model demonstrated that CD-31 staining was barely significant, meaning that 
neovascularity and BBB abnormality was not the only factor related to 
fluorescence accumulation. Evidence suggests that PpIX accumulates more 
in HGG compared to LGG due to the increased proliferation, disruption of the 
BBB, neovascularization, differential expression of membrane transporters, 
and intracellular enzymes [34, 60, 79, 81]. Selective accumulation of ALA-
induced PpIX between normal brain and tumor tissue provides necessary 
contrast and gradient for tissue delineation [28, 81-83, 95]. Intra-operative 
imaging of PpIX fluorescence allows the neurosurgeon to visualize tumor and 
thus optimize the potential for maximal resection (Fig. 1-2) [13, 45, 64, 78, 
81, 83, 90, 92, 93]. 
Multiple studies have aimed to assess the effects of ALA fluorescence-
guided glioma resection on the extent of gross total resection and 
progression-free survival (PFS) [13, 79]. 
A randomized controlled multicenter phase III trial was conducted by the 
ALA-Glioma study group and results published in 2006 [79]. In this trial, 322 
patients with suspected malignant gliomas were enrolled and randomized to 
conventional white-light microsurgery (N=161) compared to 5-ALA 
fluorescence-guided resection (N=161). The patients were administered ALA 
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orally at a dosage of 20 mg/kg body in 50 mL of water 3 hours before 
induction of anesthesia. Surgeons conducted resection as completely as was 
thought safe and feasible based on imaging and their experience. Volumetric 
analysis of the preoperative and postoperative MRI studies were conducted 
by a centralized group of radiologists who were blinded for the allocation of 
the patients in the study. Postoperatively, all patients underwent standard 
protocol fractionated RT with the same recommended dose within 14 days of 
surgery. CHT protocols were given only to those with tumors of known 
susceptibility [79]. MRI assessed the extent of tumor resection within 72 
hours and at 6 months. These patients were evaluated for PFS, residual 
tumor, overall survival (OS), neurologic deficit, and side effects. Full analysis 
was conducted on 270 patients with a mean follow-up of 35.4 months. This 
study demonstrated a 29% overall reduction in the number of patients with 
residual tumor on early MRI in the ALA group compared to the group given 
standard surgery under white light. PFS at 6 months was higher among the 
patients assigned to ALA compared to white light. Each of these findings was 
statistically significant. The OS, however, did not significantly differ between 
groups. 
Despite the reported benefits in terms of improved rates of GTR with 
application of ALA, this technology has limitations, mainly based on 
subjective fluorescence interpretation, especially at tumor margins. Most 
studies have revealed high sensitivities and specificities for areas of intense 
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fluorescence. However, specificity tends to be lower in areas of vague 
fluorescence at the tumor margins.  
Furthermore, the distorting optical properties of spatially heterogeneous 
tissue lead to subjective interpretation of PpIX fluorescence. This 
phenomenon is a limitation of this technique as currently practiced. Both 
excitation light and fluorescence emissions, as attenuated in tissue, make the 
detected fluorescence highly prone to subjectivity. This subjective 
fluorescence significantly decreases the correlation between the true levels 
of fluorophore and the visualized fluorescence. This phenomenon, which is 
dependent on the intrinsic metabolic and structural tissue changes that cause 
selective accumulation of PpIX, is partly responsible for reduced sensitivity 
and specificity reported in the above studies. Thus in the series published by 
Hefti et al. [24], tissues with a solid visualized fluorescent signals showed a 
sensitivity of 98% and a specificity of 100%; these values decreased to 76% 
and 85%, respectively, for vague fluorescence. Specificity limitations due to 
biological reasons such as nonspecific accumulation of PpIX in abscesses, 
metastasis, lymphoma, and necrotic tissue have also been reported [89]. 
This phenomenon may be related to inflammation and infiltration by reactive 
astrocytes and macrophages [50, 64, 79]. 
Occasionally, HGG may also not demonstrate PpIX fluorescence after 5-ALA 
administration [24]. In these cases, a tight BBB is thought to limit 5-ALA 
reaching tumor cells, preventing consistently successful fluorescence [21, 
26]. Novel developments using quantitative methods may allow improved 
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detection and quantitative determination of PpIX levels which would minimize 
this limitation [24, 45, 93, 95]. Valdes et al. [95] reported the use of an 
intraoperative probe to estimate the absolute concentrations of PpIX, 
correcting for the distorting effects of tissue optical properties. This study 
across a range of tumor histologies showed a statistically significant 
improvement (p<0.0001) in detection accuracy for tumor of 87% (specificity = 
92%; sensitivity = 84%) compared with 66% (specificity = 100%; sensitivity = 
47%) using conventional visual fluorescence imaging. An additional study by 
this group showed a statistically significant correlation between increasing 
quantitative levels of PpIX and cellular proliferation and histopathological 
grade in gliomas (WHO grade I-IV), further demonstrating the need for 
quantitative methods to detect the more aggressive regions of tumor [93]. 
Another phenomenon that should be remarked is photobleaching. This is the 
chemical degradation of a fluorophore that results from exposure to light [44]. 
The stronger the intensity, the longer the exposure, and the lower the 
concentrations and photochemical stability of the fluorophore, the more likely 
is the risk of photobleaching. The operator’s interpretation of fluorescent 
signal is also influenced by photobleaching of PpIX. This bleaching effect is 
mainly relevant at the tumor margins where PpIX concentrations are low [89]. 
Other factors may also limit the reliability of PpIX fluorescence. Such 
fluorescence covered by non-fluorescent tissue (normal thin brain tissue or 
blood) may be overlooked during resection [24, 89] as blue-violet light has a 
penetration power of only about 0.5 mm from the tissue surface [24]. 
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Moreover postoperative management of patients undergoing ALA 
fluorescence can be demanding too. To avoid erythema induced by the 
drug’s phototoxicity, patients are currently limited to low-light conditions for 
24 to 48 hours after surgery [60, 78, 89]. Usually 5-ALA is administered orally 
2 to 3 hours before tumor resection as the fluorescent labeling of the tumor 
cells is based on an enzyme-kinetic conversion which limits the use of 5-ALA 
in emergency cases [24] and can inconvenience surgical schedules. 
Finally, but not less important, at this stage 5-ALA is not approved yet by the 
Food and Drug Administration (FDA) for surgical resection of brain tumors 
and it is not available in every center due to the mandatory certification 
needed and to its cost (around 900 Euros for each vial).  
 
3.3.2 Hypericin 
Hypericin is a photosensitizer and fluorescent dye that has demonstrated 
preferential accumulation in malignant tissue [56, 63, 65]. Ritz et al. [63] 
recently demonstrated the potential advantages of hypericin in fluorescence-
guided recurrent glioma resection. They performed a 5-patient phase I study 
and injected a water soluble formulation of hypericin (0.1 mg/kg body weight) 
6 hours before surgery. 
Using a modified operating room microscope, they were able to distinguish 
tumor tissue from normal brain using the red fluorescence induced by 
hypericin. Histopathological review of 110 tissue samples demonstrated a 
specificity of 90% to 100% and sensitivity of 91% to 94%. No side effect with 
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intravenous (i.v.) administration of hypericin was evident. Future studies with 
larger cohorts of patients will further elucidate the utility of hypericin for 
fluorescence-guided surgery of gliomas. 
  
3.3.3 Indocyanin Green 
Indocyanin green (ICG) is a cyanine dye used largely for ophthalmologic 
purposes and has been established as the standard for visualization of 
choroidal and retinal pathologies [59, 75]. ICG binds strongly to plasma 
proteins, accounting for its slower vascular leakage within tissues. It resides 
within the vasculature for a longer period of time in the tissues with higher 
blood flow, allowing for intraoperative angiographic visualization [22]. ICG is 
metabolized in the liver and excreted via the hepatobiliary system with a half-
life of approximately 3 to 4 minutes [75]. Although it has a low toxicity profile, 
i.v. administration can cause side effects, including sore throat, hot flashes, 
and occasional anaphylaxis. ICG has an excitation peak around 800 nm and 
a major emission peak of 830 nm in tissue, and this lower frequency (longer 
wavelength) light allows deeper penetration of excitation light and permits 
ICG angiography to detect fluorescence emitted from deeper tissues to 
image patterns of circulation [22, 75]. ICG fluorescence is not visualized 
through the surgeon’s viewing binoculars since its fluorescence (830 nm) is 
not in the visible range of the electromagnetic spectrum, but rather requires 
special near infrared cameras for detection and analysis software for image 
display. 
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The ability of ICG to stain and demarcate brain tumor margins has been 
investigated in rat glioma models [22, 31]. These studies showed that i.v. 
ICG allowed demarcation of implanted glioma from normal adjacent brain 
parenchyma. Additionally, tissue staining coincided with the histologic 
margins within 1 mm at the brain tumor interface, and minimal residual tumor 
tissue was identified after resection of stained tissue. These preclinical 
studies suggested that ICG could function as a potential adjunct for 
intraoperative fluorescent delineation of brain tumor margins [31]. Based on 
these animal models, Haglund et al. [22] reported on 9 patients with LGG 
and HGG who underwent tumor resection using ICG fluorescence. In this 
study, a maximum dose of 2 mg/kg of ICG was i.v. administered. They used 
enhanced optical imaging and offline interpretation of the pictures. Optical 
imaging of the resection margins in malignant tumors showed faster ICG 
uptake and slower clearance within the tumor as compared with normal 
brain. This phenomenon was more pronounced among higher-grade tumors. 
After resection, optical imaging of the tumor margins was obtained. The sites 
with delayed clearance were biopsied. Histopathological analysis of these 
samples was positive for tumor. Despite of some promising initial findings, 
this technology is cumbersome and images need to be analyzed off-line. No 
other investigations using enhanced optical imaging with ICG for glioma 
surgery have been reported. However, ICG videoangiography has become 
an invaluable tool in vascular neurosurgery [19] and it has been used as an 
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intraoperative tool to define the vascularity associated with some tumors [18, 
31]. 
 
3.3.4 Fluorescein Sodium 
Fluorescein is a green fluorescent synthetic organic compound which has a 
myriad of medical applications. Fluorescein sodium (NaC20H10Na2O5), in 
particular, is a water-soluble salt form of fluorescein with a major blue 
excitation peak in the region of 465-490 nm and a major green emission 
peak in the region of 510 to 530 nm [33, 45, 72]. Pathological changes in 
tissues are recognized by detection of the green-yellow fluorescence, both 
macroscopically and microscopically. Causes of increased fluorescence 
include malignancy, vascular leaking defects, pooling defects, and abnormal 
vasculature or neovascularization. Causes of low fluorescence include 
blocking defects, filling defects, and a normal BBB. The fluorescence of 
fluorescein sodium occurs naturally and may be observed by the human eye 
(at high doses) or via a modified surgical microscope [5, 72]. 
Steinwall and Klatzo [76] demonstrated that fluorescein may cross through 
an altered, but not an intact, BBB [54]. The passive diffusion of fluorescein 
beyond edematous portions and the ability for neuroglial cells to pinocytose 
fluorescein is considered very small [61]. Ginsbourg and LeBeau [20] also 
concluded that fluorescein-stained tissue was confined to neoplastic areas 
whereas cortical tissue stain was not seen at peritumoral margins.  
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It is usually available as a water-soluble dye that has been extensively used 
in the field of ophthalmology since 1961, particularly to perform retinal 
angiography, with very few side effects [41, 42, 57, 99]. Fluorescein sodium, 
however, may have side effects, especially if injected quickly or in high doses 
[51].  
Although much of its use has been limited to ophthalmology, fluorescein 
fluorescence was used as an adjunct for navigation and resection of 
intracranial tumors as early as 1947-48 [52, 53].  
The way of action of fluorescein is different from that of 5-ALA. Fluorescein 
usually accumulates in specific cerebral areas as a result of leakage from a 
damaged BBB. In the case of the MG, the invasiveness of these lesions 
changes the morphology of the BBB and disrupts its continuity along brain 
vessels modifying their permeability. This allows fluorescein to become 
concentrated specifically at the tumor site, making the tumor tissue more 
clearly visible, particularly if a dedicated filter on the surgical microscope is 
available, with a possible increase in GTR rate [1] (Fig. 3-4-5-6).  
In 1982, Murray [54] reported a study in which 23 patients underwent 
craniotomies for malignant brain tumors. During this study, 111 fluorescein-
stained and 75 non-stained tissue biopsies were reviewed for 
histopathological examination using a special arc-lighting system connected 
to a conventional surgical headlight. Of the 75 non-stained specimens, 71 
(94.7%) were negative for tumor and 4 were positive. Ninety-four (84.7%) 
fluorescent sections demonstrated neoplasia and 17 showed features 
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consistent with necrotic debris. Their results emphasized the need for further 
improvement in reliability of this fluorescent technique, especially along the 
tumor margins.  
Koc et al. [33] reported a prospective nonrandomized study to evaluate the 
influence of fluorescein sodium fluorescence-guided glioma resection on the 
extent of GTR, overall prognosis, and side effects. Of the 80 patients 
enrolled, 47 received high-dose (20 mg/kg body weight) i.v. fluorescein 
sodium after craniotomy prior to incision of the dura, whereas in the second 
group (n = 33), standard resection was conducted. Using this high dose of 
fluorescein, these authors used a standard operating room microscope to 
visualize the fluorescent signal without a filter or special camera. 
Postoperatively, all patients underwent fractionated RT with the same 
recommended dose to the lesion within 20 days of surgery. The results 
showed a significant increase in the number of patients receiving GTR (83% 
versus (vs) 55%) with administration of fluorescein; however, there was no 
statistically significant difference in OS between the two groups. 
Shinoda et al. [73] reported GTR in 84.4% of patients receiving fluorescein 
sodium compared with 30.1% in those with conventional white light imaging. 
Among the patients presenting with removable lesions, GTR was achieved in 
100% of patients pretreated with fluorescein sodium compared to 44.8% 
without. Despite these encouraging results, there was no observed difference 
in the overall prognosis. There were no significant side effects noted in these 
studies. 
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The results of these studies in terms of non-significant impact on OS appear 
to be similar to those reported by the multicenter phase III randomized trial 
conducted by the ALA-Glioma Study Group. 
Kuroiwa et al. [40] assembled an intraoperative microscope with the ability to 
enhance fluorescence intensity and normal-to-tumor tissue contrast, but the 
equipment was cumbersome and impractical at the time it was designed. 
Due to its small molecule size and reversible binding to albumin and red 
blood cells, fluorescein sodium may leak extravascularly, leading to staining 
of peritumoral regions. More recently, fluorescein conjugated to albumin has 
been used to increase the concentration gradient in the tumor/brain interface 
and therefore facilitate resection. A clinical trial of a small group of patients 
(n=13) receiving 5-aminofluorescein-human serum albumin conjugate has 
demonstrated promise in improving the extent of resection [35]. 
Fluorescein is much less expensive compared to 5-ALA (5 Euros for each 
vial) and can be easily administered i.v. at the moment of anesthesia 
induction. Few side effects have been reported in the ophthalmologic 
literature [41, 42, 57, 99]. 
A brief comparison between 5-ALA and fluorescein with their main 
characteristics is reported in Table 1. 
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4. METHODS 
 
4.1 Study design 
Based on the aforementioned characteristics, sodium fluorescein was 
chosen to carry out a prospective phase-II trial (FLUOGLIO) with a two-stage 
Simon design in order to evaluate the safety and to obtain initial information 
about the efficacy of fluorescein-guided resection of MG using a dedicated 
fluorescence kit integrated in the surgical microscope.  
The study was registered on the European Regulatory Authorities website 
(EudraCT No. 2011-002527-18). 
 
4.2 Patient population 
Inclusion criteria of the FLUOGLIO trial were: 1) Patients age ranging from 
18 to 75-year old; 2) with suspected, newly diagnosed, untreated HGG, 
based on a recent (less than 14 days) brain MRI with and without i.v. 
paramagnetic contrast agent administration with volumetric sequences; 3) 
located as to enable complete resection of the whole contrast-enhancing 
area as decided by individual study surgeon were eligible to participate in the 
FLUOGLIO trial.  
Exclusion criteria were: 1) histological diagnosis different from HGG (grade III 
glioma, Anaplastic astrocytoma (AA) or grade IV glioma, GBM); 2) tumors 
starting from the midline, basal ganglia, cerebellum, or brain stem; 3) 
multifocal tumors; 4) the presence of a large, non-contrast enhancing area, 
24 
 
suggesting LGG with malignant transformation; 5) medical reasons 
precluding MRI (pacemaker, prostheses not suitable for MRI, at cetera); 6) 
inability to give consent because of dysphasia or language barrier; 7) 
Karnofsky performance scale (KPS) 60 or less; 8) renal insufficiency; 9) 
hepatic insufficiency; 10) history of active malignant tumors at any other body 
site. 
The sample size and stopping rules were determined according to a minimax 
Simon two-stage design, with 80% power and α=5%, in which a response 
rate (proportion of tumor complete resections) of ≥50% was considered 
promising and a response rate of ≤30% was unacceptable. 
In the first stage, it was foreseen that 15 patients should be enrolled, and, in 
case five or fewer responses were observed, further study should be 
terminated because of lack of treatment efficacy. Otherwise, an additional 31 
patients should be enrolled for a total of 46.  
At the end of the second stage, if 18 or fewer responses were observed the 
treatment would be rejected, whereas if 19 or more responses were recorded 
the treatment could be considered sufficiently active to warrant further study. 
The first patient was enrolled in September 2011. All patients gave written 
informed consent, and the FLUOGLIO study was approved by the Ethics 
Committee of the Foundation IRCCS Neurological Institute Carlo Besta of 
Milan, Italy, and registered on the European Regulatory Authorities website 
(see previous paragraph). 
25 
 
Twenty-eight patients were screened for participation in this prospective trial. 
There were 18 males and 10 females, ranging from 45 to 74-year old 
(median 63). Four patients were excluded from the study: two of them due to 
histological diagnosis different from a HGG (one lymphoma and one PNET). 
In the other two cases some residual fluorescent tissue was left during the 
operation: the first case was a left parietal GBM and a small amount of 
fluorescent tissue was left because of contralateral motor activation during 
neurophysiological monitoring, while the second one was a left mesial 
temporal HGG; in this case some fluorescent tissue was visible in the 
cerebral peduncle and in the mesencephalon and the surgeon decided not to 
resect it. 24 patients were finally enrolled (23 GBM and 1 AA).  
Clinical and neurological characteristics of the patients are described in 
Table 2. 
 
4.3 Pre- and postoperative clinical and radiological assessment 
General physical performance was recorded by the use of the KPS. Blood 
laboratory tests were included. Neurological function was assessed by Mini 
Mental State Evaluation (MMSE) and by the US National Institute of Health 
Stroke Scale (NIHSS).  
Pre-operative clinical evaluation was performed up to 14 days before 
surgery, while immediate post-operative evaluation was completed within 72 
hours after surgery. 
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All patients were submitted to pre-operative and post-operative pre- and 
post-contrast MRI (1.5-3 Tesla, Siemens), with volumetric sequences, within 
14 days before surgery, and within 72 hours after surgery. Pre-operative 
tumor volume and residual tumor after surgery were calculated by an 
independent neuroradiologist, using an open-source software (Osirix for 
Macintosh, www.osirix-viewer.com). Residual tumor was defined as contrast 
enhancement with a calculated volume more than 0,175 cm³ [79]. 
Surgery was followed by RT with concomitant and adjuvant Temozolomide 
(TMZ), according to Stupp protocol [84]. No restrictions were imposed on 
treatment after disease progression. Type and frequency of treatments after 
Stupp Protocol (IInd line CHT, further surgeries and radiosurgery) were 
recorded. 
Clinical and radiological follow-up were performed within 4 weeks after the 
end of radiochemotherapy and then every 2 months for GBM patients and 
every 3 months for AA patients. 
Clinical evaluation included the same tests performed at pre- and early post-
operative evaluation. Radiological controls included a pre and post-contrast 
MRI performed with volumetric sequences (1.5-3 Tesla, Siemens). 
Progression was defined as the occurrence of a new tumor lesion with a 
volume greater than 0,175 cm³, or an increase in residual tumor volume, 
according to the response assessment in neuro-oncology (RANO) Criteria 
[96]. 
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Due to the fact that all the patients were operated on under general 
anesthesia (GA), immediate and post-operative reaction to the administration 
of fluorescein could be evaluated only for objective data such as: 
hypotension, cardiac arrest, shock, seizures, bronchospasm and 
anaphylaxis. 
 
4.4 Surgical protocol 
At the intubation and before the skin incision, all patients included in the 
study received i.v. 5-10 mg/kg of a 20% solution of sodium fluorescein 
(Monico Spa, Italy).  
The study protocol stipulated complete resections of the fluorescent area, 
which was considered safely feasible by the surgeons. For this reason, two 
patients were excluded due to not complete fluorescent tissue removed by 
the surgeon (see above, paragraph 4.2). 
Surgery was done by using a dedicated surgical microscope (Pentero with 
fluorescence kit, BLU 400 or YELLOW 560, Carl Zeiss, Germany) that allows 
visualization of light emitted in the wavelength of fluorescein (maximum 
excitation of 494 nm and maximum emission of 521 nm). The operating room 
light should be dimmed for optimum reproduction of the fluorescent light. In 
the first 6 cases, the same fluorescence kit for 5-ALA-guided resection of 
gliomas (BLU 400) was used; in these cases a dose of 10 mg/kg of 
fluorescein was used. Since January 2012, the new fluorescence kit 
YELLOW 560, specifically designed by the Zeiss Company for excitation in 
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the wavelength range from 460 to 500 nm and for observation in the 
wavelength range from 540 to 690 nm, has been available. For this reason, 
the dose of fluorescein was reduced to 5 mg/kg. 
Neuronavigation (Treon, Tria and S7 Stealth Station, Medtronic, USA)  was 
permitted only for surgical planning, initial tumor localization and orientation 
during tumor removal, but not for EOR evaluation. 
In cases located near or in the proximity of cortical or subcortical eloquent 
areas, neurophysiological monitoring was performed as already described in 
a previous article [11]. 
The mechanism of action of fluorescein is related to the passage through a 
damaged BBB and accumulation in extracellular space. Thus, it helps in 
visualizing the pathological tissue in the same way as for contrast 
enhancement during MRI. In this study, fluorescein was injected i.v. after 
patient intubation and before skin incision. In this way, it was possible to 
avoid accumulation of fluorescein in cerebral area inadvertently damaged 
during craniotomy or dural opening. Microscope is brought in the operative 
field after craniotomy. During resection, the microscope could be switched 
alternatively from fluorescent to white-light illumination, as desired by the 
surgeon, by pressing the specific button on the microscope handgrip. 
However, with the YELLOW 560 filter it was possible to visualize the 
fluorescent signal and at the same time the non-fluorescent tissue in more 
natural color [1]. For this reason, most of the surgery was completed with the 
filter activated. Tumor resection was completed in an inside-out fashion 
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usually by ultrasonic aspiration, until all the fluorescent tissue exposed was 
removed, as considered feasible by the surgeon (Fig. 3-4-5-6). 
For patients harboring tumors located in non-eloquent areas, and giving their 
specific written informed consent, an ancillary protocol was designed in order 
to evaluate the accuracy of fluorescein in identification of tumor tissue. This 
included specific biopsies at the tumor margins (see next paragraph). 
 
4.5 Histological analysis and MGMT methylation status 
Histological analysis of the tumor was performed with standard procedures 
and classified on the basis of the current 2007 WHO classification by an 
independent neuropathologist [47]. 
For tumors located in non-eloquent areas, biopsies at the tumor margin were 
performed to evaluate the accuracy of fluorescein in tumor tissue 
identification (see previous paragraph). Specifically, for each patient, 4 
biopsy samples were performed at the tumor margin in areas located distant 
one from the other, 2 in the fluorescent and 2 in the non-fluorescent tissue in 
order to calculate sensitivity and specificity (see next paragraph). In this 
case, histological analysis was performed by a pathologist that was blind 
regarding the fluorescence characteristics of the biopsies, in order to 
discriminate between clear tumor tissue and peritumoral area (gliosis or 
tumor cell infiltration); immunohistochemistry for GFAP (glial fibrillary acidic 
protein) was also performed and proliferating index with Ki67 (MIB 1) was 
calculated as well. Methylation patterns in the CpG islands of O-6-
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methylguanine-DNA methyltransferase (MGMT) were determined as 
previously described [16]. 
 
4.5 Statistical analysis 
The sample was described by means of the usual descriptive statistics: 
mean, median and standard deviation for continuous variables and 
proportions for categorical ones. T-student test was used to compare pre- 
and postoperative clinical conditions. 
In order to evaluate fluorescein accuracy in tumor identification, sensitivity 
and specificity were calculated as follow. Sensitivity: number of fluorescent 
samples true positive (with histologically confirmed HGG)/ all samples with 
confirmed HGG. Specificity: number of non-fluorescent samples true 
negative (histologically confirmed not neoplastic)/ all samples histologically 
confirmed not neoplastic. 
PFS was calculated from surgery until disease progression and death/last 
follow-up, if censored. 6 months PFS was defined as the proportion of 
patients without radiological progression at the 6th month after surgery.  
OS was calculated from treatment onset until death/last follow-up, if 
censored. PFS and OS were estimated by the Kaplan-Meier method. 
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5. RESULTS 
 
5.1 Intraoperative fluorescence characteristics 
Even though both fluorescence kits in the Zeiss microscope (BLU 400 and 
YELLOW 560) allowed good visualization of the tumor area in all the patients 
included (Fig. 3-4-5-6-7), slight differences between the two filters do exist. 
BLU 400 is the fluorescence mode developed for 5-ALA-guided removal of 
HGG [79]. However, due to its wide range of emission and excitation, this 
filter also allowed good visualization of the light emitted by fluorescein in the 
area with BBB disruption. In particular, there was good discrimination 
between the fluorescent area, which appeared yellowish green, and the non-
fluorescent tissue, which was dark blue (Fig. 7). Nevertheless, this contrast 
was more evident through the oculars for the first surgeon. Furthermore, the 
motion capture system of the microscope allowed the video reproduction only 
at a low frame rate, consequently creating a low-quality video. In addition, the 
fact that the area surrounding the tumor appeared dark blue did not allow 
performing all the procedures with the fluorescent mode activated, as the 
surgeon would not have had perfect control of vascular structures. 
The YELLOW 560 module, on the other hand, improved visualization of the 
pathological and normal anatomy in the fluorescent mode. In fact, once the 
YELLOW 560 mode had been activated and the filters optimized for 
fluorescein (see above) moved into the microscope’s light path, specific 
defined amounts of blue and red light were mixed for generating a white light 
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impression of the non-fluorescent tissue. This allowed delineating the 
fluorescent signal (appearing greener and brighter than the one visualized 
with the BLU 400 mode) and at the same time visualizing the non-fluorescent 
tissue in more natural color, without significant differences between the 
ocular views of the first surgeon and those of the assistant. Furthermore, in 
this way, most of the procedure could be performed under filter activated, 
reducing the discomfort of switching continuously between white-light to 
fluorescence illumination to control bleeding or manipulate vessels during 
tumor resection. This reduced eye fatigue during surgery too.  
In addition, the high definition of the motion capture system allowed for good 
quality of images and video reproduction.  
In summary, the main difference between the two filters was related to the 
fact that, due to the higher specificity of YELLOW560 module, the fluorescent 
tissue appeared greener and brighter, with a dose of fluorescein that was 
reduced by the half.  
As mentioned above, the microscope is brought in the operative field after 
craniotomy. At the activation of the filter, the dura appeared fluorescent due 
to the characteristic features of its vascularization (Fig. 3). Tumor tissue 
showed an intense fluorescence, even if some necrotic parts of it could 
appear darker.  
Sometimes, in case of partly cystic lesions, the liquid inside the cyst was 
intensively fluorescent. 
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5.2 Percentage of resection 
Median pre-operative tumor volume was 33.1 cm3 (range 1.3-87.8 cm3). 20 
patients were submitted to a complete removal of all enhancing tumor as 
verified by an early postoperative MRI (83% of the cases) (Figure 8 and 
Table 2). The remaining patients had a mean tumor resection of 92.6% 
(range 82.6-99.9%) (Figure 9 and Table 2). 
 
5.3 Accuracy of fluorescein in tumor identification 
A total of 42 biopsies (22 in fluorescent tissue and 20 in non-fluorescent 
tissue) were performed at the tumor margin in 11 patients (4 biopsy in each 
patient, except one patient in which only fluorescent tissue biopsies were 
performed). Nineteen out of the 22 biopsies in fluorescent area showed clear 
HGG tissue. Nineteen out of the 20 biopsies in non-fluorescent area showed 
the absence of HGG tissue. These data were confirmed by the 
immunohistochemistry analysis: the 19 samples from fluorescent areas with 
HGG tissue showed GFAP-positive gliomatous cells, with a high Ki67 (MIB 1) 
index (range 5-25 %). Conversely, in the 19 non-fluorescent biopsies 
negative for MG tissue, immunostaining showed the presence of only non-
proliferating reactive astrocytes (Fig. 10-11). 
These data gave a preliminary estimation of sensitivity of fluorescein in 
identifying tumor tissue of 95% (19/20), and a preliminary estimation of 
specificity of fluorescein in identifying tumor tissue of 86% (19/22). 
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5.4 Reactions to Fluorescein, post-operative neurological status and 
complications 
According to the method of analysis described above, no adverse reaction to 
fluorescein administration could be registered in this cohort of patients, 
including those with different histological diagnosis that were excluded from 
the analysis. Other adverse events during the follow-up period are listed in 
table 3. 
No statistically significant difference was found between pre- and immediate 
postoperative NIHSS (1.46±0.38 vs 2.42±0.71, p=0.148) and KPS (median 
90 vs 80, p=0.145).  
In the early post-operative period (since the first post-operative month), three 
patients presented a complication. One patient with left occipital GBM (n.1) 
developed an entrapped temporal horn 16 days after surgery that required 
ventriculo-peritoneal (VP) shunt. One patient with left frontoinsular GBM (n.8) 
developed post-operative hemiplegia and aphasia due to a small infarction in 
the internal capsule and was sent to rehabilitation with improvement in 
aphasia and movement in the right limb. One patient with right frontal GBM 
(n.18) presented a post-operative infection of the bone flap, requiring wound 
revision and antibiotic therapy. 
 
5.5 PFS and OS 
Nineteen out of 24 patients completed post-operatively the Stupp protocol. 
After a median follow-up of 12 months (range 2-27 months), estimated 6 
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months PFS was 71.4% (60.6-82.2%) (Figure 12). Eleven patients died 
during the follow-up period for tumor progression (10 cases) or for unrelated 
cause (myocardial infarction in one case, n. 15). Median survival was 
estimated in 11 months (Figure 13). 
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6. DISCUSSION 
 
6.1 Impact of EOR on the outcome of MG patients 
There is evidence in the literature that EOR has an impact on PFS and OS 
for patients with MG, but no Class I data are available. Lacroix et al [43] 
retrospectively analyzed a database of 416 patients with GBM. They 
concluded that an EOR of 98% or more was associated with a survival 
advantage (median survival 13 months vs 8.8 for less than 98%, p<0.0001). 
Sanai et al [67] retrospectively reviewed a series of 500 patients with GBM. 
They found a stepwise correlation between EOR and OS starting at an EOR 
of 78% with 95% and greater EOR being the strongest predictor of OS. 
Nevertheless, complete resection, intended as the surgical removal of the 
whole enhancing mass on the preoperative MRI, the so called GTR, was 
reported to be feasible only in a low percentage of cases [43, 48], due to 
intraoperative difficulties in tumor tissue recognition at the margins of 
resection [89]. In particular, in the retrospective series published by McGirt et 
al in 2009 [48], considering patients operated on in the period 1996-2007 and 
excluding locations precluding a complete removal, a GTR was feasible only 
in 39% of the cases at the first diagnosis. These results were similar to the 
ones from the control group of patients of the 5-ALA study, operated on 
without the aid of fluorescent visualization, in which a complete resection was 
reported to be feasible only in 36% of the cases [79]. 
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The 5-ALA study represented a unique opportunity to study the impact of 
EOR in OS.  
Stummer et al. [80] published a follow-up study adjusted for bias using the 
data from the 5-ALA randomized controlled trial. For this purpose, the 
authors re-stratified the patients from both the 5-ALA and white light groups 
based on complete versus incomplete resection, resulting into two 
homogeneous cohorts with well-matched characteristics. The analysis 
revealed treatment bias in terms of younger patients and those with tumors in 
non-eloquent areas receiving more complete resections. Patients without 
residual tumor survived longer (16.7 vs 11.8 months, p<0.0001). This study 
provided level 2b evidence that complete resection had a significant impact 
in OS. Survival within the incomplete resection group based on EOR was not 
analyzed. 
The use of fluorophores has been designed as a surgical adjuvant to 
enhance tumor visualization increasing the rates of GTR and thus attempting 
to improve OS [45].  
The only randomized study that has attempted to investigate the impact of 
fluorescence-guided resection in EOR and PFS is the phase III randomized 
controlled trial conducted by Stummer et al [79]. This trial was designed to 
compare rates of GTR with 5-ALA fluorescence vs standard white light 
microsurgical resection. In this study, GTR was achieved in 65% of patients 
in the 5-ALA group as opposed to 36% in the white light group. Results 
showed a statistically significant increase in PFS for the 5-ALA group (5.1 
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months) vs the white light group (3.6 months). However, there was not a 
significant difference in OS (15.2 months for 5-ALA group vs 13.5 months for 
the white light group). The study was underpowered for the analysis of this 
variable. It must be noted that both arms in the study had an OS equal or 
superior than other large series published that included adjuvant 
chemoradiation [67, 84]. Overestimation of GTR is unlikely, since the 
analysis of postoperative MRI studies were conducted by a blinded 
independent group of radiologists. However, only tumors with a distinct ring-
like pattern of contrast-enhancement and a core area of reduced signal were 
included in the study. Tumors of the midline, basal ganglia, cerebellum, brain 
stem, multifocal contrast-enhancing and significant non-contrast-enhancing 
areas were excluded. This pre-operative assessment, made by the study 
surgeons, might have led to inclusion in both groups of tumors more 
amenable to GTR, with or without fluorescence. Also, tumors located in 
eloquent areas were 53% for the 5-ALA group and 59% for the white light 
group. This proportion is lower than that reported in other large series, such 
as Sanai et al. [67], who reported 69%. All these factors might have 
contributed to very aggressive resections with very small residuals in the 
control arm (median residual volume 0.7 cm3), thus making it difficult to prove 
a significant difference with the fluorescence-guided arm. 
Another fluorophore that has been extensively used to increase tumor 
visualization in HGG surgery is sodium fluorescein. 
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6.2 Literature review on fluorescein applications for MG surgery 
By analyzing the data available in the literature, three major applications of 
sodium fluorescein during surgery for MG could be documented: 
Fluorescein-Guided resection of MG with white-light illumination; 
Fluorescein-Guided Resection of MG with a surgical microscope equipped 
with a dedicated filter for fluorescein; Confocal Microscopy for intraoperative 
histopathological analysis on MG. 
 
6.2.1 Fluorescein-Guided resection of MG with white-light illumination  
The first reported application on the use of fluorescein during surgery of MG 
was described by Moore in 1947 [52, 53]. In this study [52], 46 patients 
received 1 gr of fluorescein intravenously immediately before or during 
ventriculography, in order to confirm the location of subcortical tumors. The 
majority of tumors detected by needle biopsy were malignant astrocytomas. 
The material sampled suggested the presence of tumors sometimes by direct 
white light visualization, but, usually, by UV light directly in the operating 
room. The biopsy was then verified by histological examination, with a 
correct diagnosis assured by fluorescein visualization in 96% of cases. 
Similar applications were reported in subsequent series [2, 86]. 
The accuracy of fluorescein to identify tumor tissue was systematically 
studied by Murray KJ, by performing a total of 186 biopsies in 23 patients 
with brain malignancies. In that study, he obtained a sensitivity of 96% and 
specificity of 81% [54].  
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The use of fluorescein to improve the percentage of resection of MGs has 
only been explored in recent years. Some studies were performed without 
the aid of a specific illumination light and filter to allow for a better 
discrimination of fluorescein fluorescence [9, 33, 73].  
Shinoda et al in 2003 reported the first retrospective analysis on a series of 
32 patients operated on with the aid of fluorescein, but without a special filter 
adapted to the surgical microscope [73]. The operation was therefore 
completed under white light illumination and with standard surgical 
microscope. In this case, a high-dose of fluorescein was intravenously 
administered (20 mg/Kg) in order to detect fluorescence in the surgical field, 
at the time of dural opening. For this reason, immediately after intravenous 
injection, the normal cortex, vessels, dura mater and tumor were stained 
yellowish, but after approximately 5 minutes only the tumor retained the 
yellow dye. The yellow appearance was different inside the tumor, with the 
center more deeply stained and the periphery faintly stained. However, even 
the periphery appeared clearly discernable from the negative peritumoral 
area. This difference in fluorescence seemed to be correlated to the 
histological characteristics of the tumors. In fact, in 4 of the cases analyzed 
by histology, the authors found GBM tissue in the center deeply stained area, 
while less dense tumor cells and scattered endothelial proliferation in the 
faintly stained area. Based on post-operative MRI, interestingly enough, the 
percentage of GTR was almost 85%, and it was significantly better than the 
percentage of 30% obtained by the same authors in a historical control group 
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operated without fluorescein. However, no statistically significant difference 
in survival could be found between these groups.  
Similar results were reported by Koc et al [33], who described the result of a 
prospective analysis on two non-randomized groups, one of which operated 
by the aid of fluorescein (20 ml/Kg at the time of dural opening) without a 
specific filter on the microscope (group 1), and one without fluorescein 
administration (group 2). The percentage of GTR based on post-operative 
MRI was 83% in group 1 and 55% in group 2. Both groups were submitted 
only to RT, without concomitant or adjuvant CHT. OS was therefore poor, 
with 44 weeks in group 1 and 42 weeks in group 2, without a significant 
difference. A similar trial was performed by Chen at al [9], reporting a 
significant increase in GTR in patients undergone fluorescein-guided surgery 
for MG. A total of 22 patients were enrolled in this study, divided into the 
study group (n=10) which included patients that received i.v. fluorescein 
injection (15-20 mg/Kg at the time of dural opening) and the control group 
(n=12) without fluorescein administration. GTR rate was 80% in the study 
group and 33.3% in control group. No complications were detected by Chen 
et al [9] in a study where pre-operative allergy test were performed in order to 
avoid any possible allergic reactions. Persistent yellow staining of skin, 
mucosa and urine were the only adverse events observed by Shinoda et al 
[73] in the next 24h after operation. Even though low complication rate has 
been described in the ophthalmologic field [41, 42, 57, 99], some side effects 
can occur after high-dose fluorescein administration. Few  anaphylactic 
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reactions have been reported with severe bradycardia and hypotension [14, 
88]. 
These data are summarized in table 4. 
 
6.2.2 Fluorescein-Guided Resection of MG with a surgical microscope 
equipped with a dedicated filter for fluorescein  
Due to the specific characteristics of fluorescein, with a maximum absorption 
at 494 nm and maximum emission of 521 nm, some filters have been 
developed to help in the discrimination of fluorescence during surgical 
approaches for MG removal.  
The first experiences were made with filters not directly integrated in the 
surgical microscope, but adapted to guarantee a visualization of fluorescein 
that was coherent with its absorption and emission wavelength peaks. 
Kabuto et al in 1997 used two filters for the excitation and emission of 
fluorescein that could be manually fitted to and removed from a surgical 
microscope during operation for MG in 5 cases [29]. These authors injecting 
high dose of fluorescein (1 gr i.v.), reported a clear visualization of the tumor 
under the filter, but they also found a faint yellow color under white light 
illumination. Observation during tumor removal could be changed to ordinary 
white light illumination by removing the filters, in order to perform surgical 
maneuvers requiring a better visualization of the structures in and around the 
tumors, such as vessels.  
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A similar combination of high-dose fluorescein (20 mg/Kg upon dural 
opening) and excitation and barrier filters inserted in the operating 
microscope (OME-9000, Olympus) was proposed more recently for GBM 
removal, by Okuda et al [58]. Ten consecutive patients were included in this 
trial, and no side effects were described. Depending on the resection 
requirements, the high fluorescein dose allowed surgical maneuvers to be 
performed both in fluorescence mode and under normal white xenon-light 
illumination. According to these authors this seemed to improve the reliability 
of surgical removal of GBM. In all the 5 cases studied with an intended GTR, 
this was confirmed post-operatively. 
Kuroiwa et al described for the first time a technique in which the 
fluorescence filter was directly integrated in the microscope (Zeiss OPMI) 
[40]. In this study as well, visualization could be switched during operation 
from filter to white light illumination. In addition, due to specificity of the filter 
for absorption and emission wavelength of fluorescein, these authors were 
the first to use a reduced dose of i.v. fluorescein, specifically 8 mg/kg, which 
was injected upon dural opening. As reported by Shinoda, without filter 
visualization [73], they documented immediately after injection a 
fluorescence staining in the arteries, veins of the surface, brain parenchyma 
and tumor. But 5 minutes after injection the brain surface fluorescence 
lessened, and tumor removal started 20 minutes later. Ten patients were 
included in this study. In 8 cases, a complete tumor removal could be 
obtained. The same group [39] studied a larger series of 30 patients using 
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the same technique, and in 5 cases they compared the intra-operative finding 
with standard histological analysis. Fluorescein-positive areas revealed 
abnormal tumor vessels and dense tumor cells, while fluorescein-negative 
areas showed only scant tumor cells infiltration and no abnormal vessel. In a 
different paper, the same group demonstrated the application of fluorescein 
injection for frameless stereotactic biopsies of deep contrast-enhancing brain 
tumors [38].  
Since 2012, a dedicated module for fluorescein filter (YELLOW 560), has 
been specifically designed by the Carl Zeiss Company (Germany) for 
excitation in the wavelength range from 460 to 500 nm and for observation in 
the wavelength range from 540 to 690 nm, and directly integrated in the 
Pentero surgical microscope. The YELLOW 560 module improved 
visualization of the pathological and normal anatomy in the fluorescent mode 
[1]. In fact, once the YELLOW 560 mode had been activated and the filters 
moved into the microscope light path, specifically defined amounts of blue 
and red light were mixed for generating a white light impression of the non-
fluorescent tissue. This allowed for a delineation of both the fluorescent 
signal and the non-fluorescent tissue in more natural color. In this way, it was 
possible to protect the normal structures during surgical maneuvers under 
fluorescence visualization [1]. Furthermore, due to the high specificity for 
fluorescein of this filter, the fluorescein dose could be further reduced in 
clinical application [1, 69]. 
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In 2013, two papers concerning the use of Yellow 560 filters for surgery of 
MGs have been published [1, 69]. Schebesch et al [69] conducted a 
retrospective analysis on 35 patients, including 22 with MG (12 initial 
glioblastomas, 5 recurrent glioblastomas and 5 grade III gliomas), operated 
on from May to August 2012. A total of 2 ml (200 mg corresponding to 
approximately 3-4 mg/kg) of fluorescein were intravenously administered 
after bone flap removal prior to durotomy. Most of their results came only 
from a qualitative analysis and there was no definitive data presented 
regarding EOR in MG. In addition, no histological studies on fluorescent and 
non-fluorescent tissue were performed.  In this study, there were no adverse 
reactions registered. With this low-dose of fluorescein, only the urine became 
colored yellow for 6 hours post-operatively with no sclera or skin 
discoloration experienced by the patients.  
Our group was the first to propose a phase II prospective trial on fluorescein-
guided resection of MG with a dedicated filter on the surgical microscope 
(FLUOGLIO study) [1].  
These data are summarized in table 5. 
 
6.2.3 Confocal Microscopy for intraoperative histopathological analysis on 
MG 
Confocal microscopy is an innovative technology that has been developed in 
the last decade. Its introduction represents a major breakthrough in the 
conventional histopathological analysis for selected tissue biopsy. Confocal 
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microscopy has been integrated in different medical specialties, since its 
initial application in Gastroenterology, where it was used to evaluating 
endoscopically inapparent barrett’s esophagus [15, 30], or colorectal cancer 
[27]. It has also been used for endomicroscopic diagnosis of cervical 
intraepithelial neoplasia [87] or uroepithelial cancer [97]. 
Its application in neurosurgical field followed in turn. But, in order to do this, a 
specific tool needed to be developed [17, 66, 68]. The essential elements of 
this neurosurgical tool was a rigid probe containing a miniaturized scanner 
that allowed an operator-dependent specific depth-visualization that was 
usually in the range of 0-250 micron. This technical tool was handheld and 
sterilizable, and perfectly designed for neurosurgery. The scanner was 
connected to an external monitor in order to visualize the tissue against 
which the probe was directed, which was then sent to a personal computer 
unit.  
This technique allowed an in vivo visualization of the histopathological 
features and cytoarchitecture of the analyzed samples, giving a significant 
aid in the intraoperative tumor identification [17]. Furthermore this approach 
seemed to overcome the limitations presented by the traditional 
intraoperative frozen-section evaluation that can be subject of mechanical or 
chemical alteration or can present artifacts [17]. In the studies performed by 
Eschbacher J et al and Sanai N et al from the Barrow Neurological Institute 
[17, 66], the clinical protocol included 25 mg of i.v. fluorescein sodium in 
order to increase the qualitative difference of the contrast-enhanced tumor 
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margin. According to this study the imaging process was initiated 5 minutes 
after fluorescent tracer administration. Once the different surgical sites were 
studied and the images acquired, biopsy samples were taken in order to 
perform the traditional histological analysis. In the blinded study that was 
performed [17], a neuropathologist interpreted the confocal images and the 
biopsy samples. In 28 images, an accuracy of 92.9% was reported. As these 
data suggest, this relevant device was less time-consuming and it had a 
comparable sensitivity to the traditional frozen-section analysis.  
 
6.3 The FLUOGLIO study 
From the analysis of the literature, fluorescein injection seemed to be a good 
method to obtain a high rate of GTR during surgery for MG. Percentage of 
resection in the analyzed series varied from 75% to 100%. In some papers, a 
significant increase of total resection was obtained if compared with cases 
that had been operated on without fluorescein use [9, 33, 73]. In addition, 
even if the mechanism of action is not related to a specific uptake of 
fluorescein by tumoral cells (as for 5-ALA), thus allowing for the possibility of 
false positive cases (metastases, surgical trauma, et cetera), different studies 
performed with and without filters on the surgical microscope showed a high 
level of accuracy in tumor identification [1, 39, 40, 54].  
However, it needs to be noted that a proper phase III trial has not been 
published which is crucial to provide the kind of definitive data concerning 
any possible increase in PFS as well as the survival of patients operated with 
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fluorescein-guided technique. It is also important to recognize, additionally, 
that even with fluorescein-guided technique and under specific filter 
visualization, a complete removal of favorable MG is not always possible. As 
for other types of fluorescence tools currently been used in neurosurgical 
applications [18, 19], and as it has been suggested for 5-ALA [89], it is 
possible to enhance the discrimination of the pathological tissue with 
fluorescein only if it is properly exposed during the surgical approach. In two 
of the cases included in the FLUOGLIO study [1], for example, a small 
remnant was left due to its location around the corner of visualization during 
the approach. In addition, sometimes, in tumor located in close proximity to 
eloquent areas, a portion of fluorescent tissue could be left at the tumor 
margin if cortical or subcortical brain mapping shows positive responses.  
The data presented on this cohort of patients confirmed that the use of i.v. 
fluorescein during resection of HGG is safe and it is associated with a high-
rate of complete resection of contrast enhanced tumor at the early post-
operative MRI. 
Coherently with the experience of ophthalmologists for retinal angiography 
[99], and based on its known safety profile, no adverse reaction related to the 
use of fluorescein was recorded so far in the FLUOGLIO study. 
Even though no adverse reactions were found in previous small series with 
doses of 20 mg/kg of fluorescein  [73], the use of specific filters enabled 
reduction of the total dose of fluorescein injected  [1, 40, 69] with a possible 
impact on reduction of side effects. In fact, even if adverse events including 
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anaphylactic reactions after fluorescein injection have been rarely reported in 
ophthalmological and neurosurgical literatures [14, 41, 42, 57, 88, 99], no 
side effects were registered with the use of low-dose fluorescein in more 
recent papers.  
Moreover, it should be noticed that in neurosurgical application side effects 
could be even less frequent than ophthalmological cases due to the fact that 
fluorescein administration was performed with the patient intubated under 
GA.  
The volumetric analysis performed in our cohort of 24 patients with HGG on 
early postoperative MRI showed a total resection of the contrast-enhancing 
tissue in 83% of cases. These data, although still limited by the small number 
of cases and, more importantly, the absence of a control group operated on 
without fluorescein, are really promising. 
The inclusion and exclusion criteria were in fact similar to the prospective 
phase-III trial on 5-ALA by Stummer et al [79]. Specifically, patients with 
tumors located as to enable a complete resection of the contrast-enhanced 
area were enrolled. Nonetheless, the case series presented also included 
lesions in eloquent areas and with a median volume of 33.15 cm3 (Table 2). 
Therefore, it seems reasonable to consider the rate of total removal not 
related to the inclusion of small tumors in non-eloquent areas. Furthermore, 
since patients were operated on by surgeons with different levels of 
experience and skill, these results could be generalized to other 
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neurosurgical departments in the world and not be related to a hypothetical 
better result of a highly skilled surgeon. 
It should be underlined that the accumulation of fluorescein in the brain tumor 
area is related to the passage through a damaged BBB, and not to a specific 
uptake by the high grade glial cells as for 5-ALA. Therefore, as previously 
mentioned [89], this could lead to a reduced accuracy in terms of tumor 
identification. Nevertheless, different studies performed in the past with and 
without filters on the surgical microscope, showed a high level of accuracy in 
tumor identification [40]. These data were confirmed in the present series of 
biopsies of fluorescent and non-fluorescent tissue at the tumor margin, with a 
sensitivity and specificity in tumor identification that were respectively 95% 
and 86%. The use of the specific filter on the surgical microscope could have 
led to better accuracy in tumor identification. This could also explain why the 
patients did not experience a statistically significant difference in terms of 
neurological functions in the post-operative period. In addition, the new filter 
Yellow 560 allowed a dose reduction of fluorescein, due to the higher 
specificity of the filter characteristics. Theoretically, this could further reduce 
the number of side effects. 
Since the MGMT methylation signature has a relevant effect on disease 
outcome [25], its status was analyzed in all patients, being unmethylated in 
the majority of them (71%). 
Median long-term follow-up (12 months) is still not sufficient to draw a 
definitive conclusion about long-term outcome. However, preliminary data on 
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6 months PFS were promising with more than 70% of patients without 
progression. 
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7. CONCLUSIONS 
 
The analysis of the data collected so far in 24 patients, suggested that the 
use of i.v. fluorescein during surgery of HGG with a dedicated filter integrated 
in the surgical microscope is safe and could be associated to a high-rate of 
complete resection. If confirmed at the end of the study, these results will 
represent the prerequisite to build up a proper prospective randomized 
controlled phase III trial to definitively prove a positive effect of i.v. fluorescein 
on EOR of HGG. 
Finally, we could speculate that a combination of fluorescein-guided 
resection of MG by the use of a dedicated filter on the surgical microscope 
and confocal microscopy to confirm the absence of cancerous residual cells 
at the tumor margin could provide an exceptional method to extend the 
surgical removal to a cellular level. 
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9. TABLES 
 
Table 1  
Comparison between main characteristics of fluorescein and 5-ALA for 
surgery of MG. 
 
 5-aminolevulinic acid (5-ALA) FLUORESCEIN 
TYPE OF SUBSTANCE DRUG: precursor of hemoglobin DYE: sodium salt of fluorescein 
MECHANISM OF ACTION Selectively elicits the synthesis of 
fluorescent porphyrin IX in 
tumoral cells 
Passes throughout a damaged BBB 
DOSAGE 20 mg/Kg 3-10 mg/Kg 
TIME AND MODE OF 
INJECTION 
2-3 hours before surgery, orally 
administered 
At the time of surgery, i.v. administered 
 
FLUORESCENCE 
VISUALIZATION 
 
Specific Filter for visualization: 
needed (ZEISS-LEICA) 
 
Filter characteristics: good 
discrimination of fluorescent 
tissue; poor visualization of 
peritumoral area 
 
 
Specific Filter for visualization: needed 
(unless high dosage) (ZEISS) 
 
Filter characteristics: good 
discrimination of fluorescent tissue; 
visualization of peritumoral area in 
more natural colors 
EFFECT ON GTR RATE 65% vs 36% ˚ 75-100%* 
EFFECT ON PFS 6-PFS 41% vs 21.1% ˚ No definitive data available 
EFFECT ON OS No definitive data available No definitive data available 
COSTS Around 900 Euros for each vial Around 5 Euros for each vial 
 
˚ data against white light illumination derived from a randomized controlled 
multicenter study (see text). 
* data derived from the present study and available literature, including only 
case series, retrospective studies and prospective non randomized controlled 
studies. 
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Table 2 
Patients included in the FLUOGLIO study up to December 31st, 2013.  
 
 
Patient  Tumor location 
Tumor 
size (cm3) 
Histology MGMT status 
% of 
resection 
NIHSS 
pre-op 
NIHSS 
post-op 
KPS 
pre-op 
KPS 
post-op 
1 L occipital 28.0 GBM Unmethylated 100% 3 4 70 60 
2 L temporal 12.8 GBM Methylated 100% 0 0 100 100 
3 R parietal 49.8 GBM Unmethylated 100% 3 4 70 80 
4 R parietal 87.8 GBM Methylated 99.9% 7 8 70 60 
5 R frontal 12.2 GBM Unmethylated 100% 0 1 90 80 
6 L occipital 41.0 GBM Unmethylated 100% 0 0 100 100 
7 L temporo insular 31.8 GBM Unmethylated 88.6% 1 2 90 80 
8 L frontoinsular 34.5 GBM Unmethylated 100% 4 13 90 50 
9 R frontal 9.6 GBM Unmethylated 82.8% 0 3 90 70 
10 L temporal 2.4 AA Methylated 100% 1 1 90 90 
11 R frontal 20.0 GBM Unmethylated 100% 1 1 90 90 
12 R frontal 83.8 GBM Unmethylated 100% 2 1 80 90 
13 R temporal 86.1 GBM Unmethylated 100% 1 0 70 80 
14 R parietal 12.5 GBM Unmethylated 100% 1 4 100 90 
15 R frontal 69.7 GBM Unmethylated 100% 2 5 70 50 
16 L frontal 8.3 GBM Unmethylated 100% 1 2 90 70 
17 R frontal 31.8 GBM Methylated 100% 0 0 100 100 
18 R frontal 8.9 GBM Unmethylated 100% 0 0 90 90 
19 L temporal 28.8 GBM Unmethylated 100% 1 2 80 70 
20 R parietal 38.9 GBM Unmethylated 99.3% 1 2 90 80 
21 L parietal 1.3 GBM Methylated 100% 0 0 100 100 
22 R parietal 1.9 GBM Methylated 100% 0 0 100 90 
23 L frontal 18.7 GBM Unmethylaed 100% 2 2 90 80 
24 R parietal 73.5 GBM Methylated 100% 4 3 70 80 
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Table 3  
List of adverse events, treatment required and outcome. 
 
 
 
 
 
 
 
 
 
 
Pt. 
No. 
Tumor 
location 
 
Adverse event 
 
Treatment required 
 
Outcome 
Correlation to 
fluorescein 
1 L occipital 
Left temporal horn 
excluded 
 
VP shunt 
 
Complete 
recovery 
 
NO 
2 L temporal 
leucopenia after I° 
cycle of adjuvant 
TMZ 
Reduction of TMZ 
dose during II° and III° 
cycle 
 
Complete 
recovery 
 
NO 
3 R parietal 
1. lung infection 
2. extradural 
collection and brain 
edema with 
hemiparesis 
 
1. hospitalization for 
i.v. antibiotics 
administration   
2. extradural fluid 
collection and bone 
removal 
 
1. stop CHT 
2. slight 
hemiparesis 
(improved) 
 
NO 
8  L frontoinsular 
Right hemiplegia and 
aphasia 
 
Rehabilitation 
Improvement of 
aphasia and of 
right inferior limb 
paresis 
 
NO 
9 R frontal 
1. Trombocytopenia 
after I° cycle of 
adjuvant TMZ 
2. Partial motor 
seizure during RT 
 
1. Platelet transfusion 
2. Antiepileptic drug 
  
Complete 
recovery 
 
NO 
10 R frontal Brain edema after RT 
Hospitalization for i.v.  
steroids and mannitol 
administration 
 
Complete 
recovery 
 
NO 
68 
 
Table 4  
Fluorescein application during surgery for MG with white-light illumination. 
 
 
 
Fluorescein's 
application Author Year No. of pts. 
Fluorescein 
dose (mg) 
Time of Fluorescein 
injection GTR rate 
Localization of 
brain tumor 
Moore 1947 12 1000 Not specified 
Not 
examined 
Localization of 
brain tumor 
Moore 1948 46 1000 
Before 
ventriculography 
(approximately 2 
hours before surgery) 
Not 
examined 
Localization of 
brain tumor 
Belcher 1951 - - - - 
Localization of 
brain tumor 
Svien 1951 not specified 1000 not specified 
not 
examined 
Identification of 
brain tumor 
Murray 1982 
23 (14 MG) 
(for 186 
biopsies) 
1000 not specified 
not 
examined 
Resection of MG Shinoda 2003 32 20 mg/Kg before dural opening 84.4% 
Resection of MG Koc 2008 47 20 mg/kg before dural opening 83% 
Resection of MG Chen 2012 22 15-20 mg/kg before dural opening 80% 
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Table 5 
Fluorescein application during surgery for MG with specific filters in the 
surgical microscope. 
Dedicated Filter Author Year No. of pts 
Fluorescein 
dose (mg) 
Time of Fluorescein 
injection GTR rate 
manually fitted 
and removed 
Kabutol 1997 5 (3 MG) 1000 
Before tumor 
resection 
(not further specified) 
Not 
examined 
integrated in the 
microscope 
(OPMI, Zeiss) 
Kuroiwa 1998 
10 (8 with 
tentative 
GTR) 
8 mg/kg upon dural opening 100% 
integrated in the 
microscope 
(OPMI, Zeiss) 
Kuroiwa 1999 30 8 mg/Kg upon dural opening 83.3% 
integrated in the 
microscope 
(OPMI, Zeiss) 
Kuroiwa 1999 
20 (3 with 
frameless 
stereotactic 
system) 
8 mg/Kg 
before incision of the 
dura mater 
95% 
inserted in the 
operating 
microscope 
(OME-9000, 
Olympus) 
Okuda 2012 
10 (5 with 
intended 
GTR) 
20 mg/kg upon dural opening 100% 
YELLOW 560 
filter integrated in 
the microscope 
(Pentero, Zeiss) 
Schebesch 2013 35 3-4mg/kg 
after bone flap 
removal, 
prior to durotomy 
Not 
examined 
YELLOW 560 
filter integrated in 
the microscope 
(Pentero Zeiss) 
Acerbi 2013 
20 (ongoing 
trial) 
5mg/kg 
after anesthesia 
induction, 
before skin incision 
75% 
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10. FIGURES 
 
Figure 1 
 
 
Intraoperative view showing tumor cavity viewed under conventional white 
light (A) and violet-blue illumination (B). Note the different qualities of tumor 
fluorescence in the necrotic part (necrosis), in the solid very cellular part 
(solid) and at the tumor margins (vague). (From: Stummer W et al, J Neurosurg, 
2000, ref no. 78). 
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Figure 2 
 
 
Intraoperative view showing tumor fluorescence with 5-ALA at the beginning 
of surgical resection (A) and almost at the end of resection (B). Note in B the 
darker area where resection is completed (white arrow) and the fluorescent 
area where the is still tumor tissue to be removed (yellow arrow). (Adapted 
from: Li Y et al, Wolrd Neurosurg, 2013, ref no. 45). 
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Figure 3 
 
 
Preoperative (A) and post-operative (B) MRI and intraoperative images (C-H) 
of a case of left frontal GBM operated on with fluorescein-guided technique 
by the use of Yellow 560 filter. A) Preoperative axial MR (T1 with 
gadolinium), showing a left frontal partially cystic tumor, compatible with a 
diagnosis of MG. B) Post-operative axial MR (T1 with gadolinium), showing 
the complete resection of the tumor. C) Dural exposure after craniotomy with 
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white light illumination. D) Dural exposure after Yellow 560 filter activation, 
showing the yellow-green discoloration due to the fact the in dural tissue no 
BBB is present. E) After dural opening, brain parenchyma is exposed, 
without clear demonstration of the location of the tumor. F) After Yellow 560-
filter activation, there is a clear delineation of the tumor area (white arrow) 
with respect to the peritumoral brain. G) At the end of the removal, no 
residual tumor tissue is evident with white light illumination. H) The absence 
of residual tumor is confirmed by the activation of Yellow 560, showing no 
fluorescent areas.  
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Figure 4 
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Preoperative (A) and postoperative (D-E) MRI and intraoperative images (B-
C) of a case of left temporal GBM operated on with fluorescein-guided 
technique by the use of Yellow 560 filter. A) Pre-operative axial MR (T1 with 
gadolinium) showing a huge mass of enhancing tumor, compatible with a 
diagnosis of MG. B) During removal with ultrasonic aspiration with white light 
illumination, it was difficult to clearly distinguish tumor tissue (white arrow) 
from peritumoral areas. However, the activation of Yellow 560 filter (C) 
allowed for the identification of the fluorescent tumor (white arrow). D-E) 
Post-operative axial MR T1 images without (D) gadolinium showed the 
surgical cavity with hyperintensity due to hemoglobin products, while T1 with 
gadolinium (E) confirmed the absence of contrast-enhancement, thus 
showing GTR of the tumor. 
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Figure 5 
 
 
 A-B) Intraoperative view during a right frontal GBM resection. With the 
YELLOW 560 filter activated (A) it is possible to visualize an area of tumor 
that still needs to be removed (red arrow); the same picture with white light 
illumination (B) and the tumoral tissue (black arrow). C) Preoperative axial 
T1-weighted MR with i.v. contrast administration showing a right frontal GBM 
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(tumor volume 8.93 cm3). D) Early (<72 hours) postoperative axial T1-
weighted MR with i.v. contrast administration showing a complete tumor 
resection without any area of contrast enhancement. 
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Figure 6 
 
 
Intraoperative pictures of a right frontal GBM, operated on with the YELLOW 
560 fluorescence kit. The patient is in supine position with the head turned 
toward the left; at the left side is the vertex (up), while on the right is the 
sylvian fissure and temporal lobe (down). A) The fluorescent area is bright 
yellowish green, the normal brain parenchyma surrounding the tumor is 
slightly dark, but with similar colors as with normal white light view. B-C) 
Intraoperative pictures during tumor removal: at the inferolateral margin of 
the tumor, the area depicted in B (black arrow) appears similar to the 
surrounding zone; after the YELLOW 560 filter has been activated (C), the 
same area appears fluorescent (white arrow), thus indicating tumor tissue 
that still needs to be removed. 
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Figure 7 
 
 
Intraoperative pictures of a right parietal GBM, operated on with the BLU 400 
fluorescence kit. The patient is in the left lateral position; at the bottom is the 
vertex (up) and on the left the frontal lobe, anterior to the tumor (ant). A) After 
dural opening in normal white light view. Note the superficial vascularization 
of the tumor area (arrowhead) with arterialized vein on the post-central 
sulcus (arrow). B) The same superficial area as in A, after activation of BLU 
400 filter. The tumor area is delineated as a yellowish zone, surrounded by 
normal blue parenchyma. C) During tumor resection with the two-sucker 
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aspiration technique, at the posterior-inferior margin of the tumor. All the 
exposed areas (a and b) appear similar. D) After activation of the BLU 400 
filter, the b area is fluorescent (arrow), while the a area is not. 
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Figure 8 
 
 
A) Preoperative axial T1-weighted MR with i.v. contrast administration 
showing a left posterior temporal GBM (tumor volume 12,8 cm3). B) Early 
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(<48 hours) postoperative axial T1-weighted MR with i.v. contrast 
administration showing a complete tumor resection without any area of 
contrast enhancement. C-D) 24 months follow-up axial T1-weighted MR with 
i.v. contrast administration without any tumor recurrence. 
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Figure 9 
 
 
 A) Preoperative axial T1-weighted MR with i.v. contrast administration 
showing a right frontal GBM (tumor volume 38.92 cm3). B-C) Early (<48 
hours) postoperative axial T1-weighted MR with i.v. contrast administration 
showing a very extensive, but not complete tumor removal (red arrow in C); 
residual tumor volume was 0.28 cm3. 
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Figure 10 
 
 
 Histological pictures (hematoxylin-eosin) of biopsies at the tumor margin 
from patient no. 4 (A-B) and no. 11 (C-D). A and C were obtained from 
biopsies of fluorescent tissue at the tumor margins and showed a sample of 
true GBM (A) and nervous tissue widely infiltrated by HGG cells (C) (both 
considered as true positive for the estimation of sensitivity). B and D were 
obtained from biopsies of non-fluorescent tissue at the tumor margin and 
showed normal nervous tissue (B) or some gliosis (D) (both considered as 
true negative for the estimation of specificity). 
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Figure 11 
 
 
Immunostaining pictures of biopsies at the tumor margins in patient no. 11. A 
and B were obtained from biopsies of fluorescent tissue and showed GFAP-
positive gliomatous cells (A) with high proliferation index by Ki67 (MIB1) 
immunostaining (B). C and D were obtained from biopsies of non-fluorescent 
tissue and showed only reactive astrocytes (C) without proliferating nuclei at 
Ki67 (MIB 1) immunostaining (D). 
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Figure 12 
 
 
Kaplan-Meier curve of PFS. 
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Figure 13 
 
 
Kaplan-Meier curve of OS. 
